For Chronic Myeloid Leukemia (CML) patients, Ponatinib HCL represents a powerful treatment option. This targeted therapy tackles specific mutations that drive the cancer's growth. However, a significant hurdle exists: ensuring affordable access to the drug's Active Pharmaceutical Ingredient (API), ...
Share this page with your family and friends.